Private Equity
Venture debt is exploding at a rate of between 20 and 30 percent year-over-year. The market is predicted to swell to $10.1 billion this year, about 20 percent higher than 2018 and double from 2016.
2 min read · 04 October 2019
Activity slows for new funds as only seven emerging managers raise just $104 million in previous two weeks
2 min read · 04 October 2019
1 min read · 03 October 2019
2 min read · 03 October 2019
Woburn, Massachusetts-based Frequency Therapeutics, a biotech firm, has raised about $84 million for its IPO after pricing its 6 million share at $14 per share. The stock began trading October 3, 2019 on the NASDAQ under the ticker symbol "FREQ." J.P. Morgan, Goldman Sachs and Cowen are the lead underwriters. Frequency's pre-IPO backers include Perceptive Advisors.
3 min read · 03 October 2019
Menlo Park, California-based Adicet Bio Inc, a biopharmaceutical company, has raised $80 million in Series B financing. The investors include aMoon2 Fund, Regeneron Pharmaceuticals, Inc., Johnson & Johnson Innovation – JJDC Inc, Samsung Venture Investment Corporation, OrbiMed, Novartis Venture Fund and Pontifax.
1 min read · 03 October 2019
Seattle-based vaccines developer Icosavax has secured $52 million in Series A funding. Qiming Venture Partners USA led the round with participation from Adams Street Partners, Sanofi Ventures and NanoDimension.
1 min read · 03 October 2019
Longliv Ventures is investing $5 million in DayTwo, a microbiome human discovery platform. DayTwo's other investors include Cathay Innovation and Samsung NEXT.
1 min read · 03 October 2019
South San Francisco-based Tenaya Therapeutics Inc, a provider of curative therapies that target the underlying causes of heart disease, has secured $92 million in Series B financing. Casdin Capital led the round with participation from other investors that included GV and The Column Group.
1 min read · 03 October 2019
AmacaThera, a Toronto-based developer of injectable hydrogel technology for medical applications, has secured US$3.6 million in seed funding. The investors were Sprout BioVentures/ Viva Biotech, Grey Sky Venture Partners and Toronto-based Lumira Ventures. AmacaThera is currently a resident company at the Johnson & Johnson Innovation – JLABS incubator.
1 min read · 03 October 2019
